Pharmaceutical

Anti-RANKL Monoclonal Antibody by Jiangsu Pacific Meinuoke Bio-Pharmarceutical for Osteoporosis: Likelihood of Approval

Anti-RANKL Monoclonal Antibody is under clinical development by Jiangsu Pacific Meinuoke Bio-Pharmarceutical and currently in Phase I for Osteoporosis.

Jun 20, 2024 - 04:00
Anti-RANKL Monoclonal Antibody by Jiangsu Pacific Meinuoke Bio-Pharmarceutical for Osteoporosis: Likelihood of Approval
Anti-RANKL Monoclonal Antibody is under clinical development by Jiangsu Pacific Meinuoke Bio-Pharmarceutical and currently in Phase I for Osteoporosis.
Read the original article

Tags:

Previous Article

ILution travoprost by Glaukos for Ocular Hypertension: Likelihood of Approval

Next Article

IBI-343 by Innovent Biologics for Solid Tumor: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Risk adjusted net present value: What is the current va...

Nov 18, 2023

Dren Bio and Novartis link on bispecific antibodies for cancer

Dren Bio and Novartis link on bispecific antibodies for...

Jul 26, 2024

Covid-19: Anti-inflammatory drugs do not lead to a swifter hospital exit

Covid-19: Anti-inflammatory drugs do not lead to a swif...

Jul 11, 2023